Zobrazeno 1 - 10
of 19
pro vyhledávání: '"John W G, van Putten"'
Autor:
Marco van Londen, Elizabeth Roosma, Stefanie Vogels, John W. G. van Putten, Wilbert M. T. Janssen
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-5 (2022)
Abstract Background Targeted therapy with anaplastic lymphoma kinase inhibitor alectinib has become standard therapy for selected patients with non-small cell lung carcinoma. Few data are available on the renal effects of alectinib. We report on a ca
Externí odkaz:
https://doaj.org/article/d2d1a8ce93f94657ba480af6caaee543
Autor:
Robert Peric, Vincent van der Noort, Harry J.M. Groen, Anne-Marie C. Dingemans, Nico van Walree, Franz M.N.H. Schramel, Christi M.J. Steendam, Pepijn Brocken, Stijn L.W. Koolen, G.D. Marijn Veerman, John W. G. van Putten, Ron H.J. Mathijssen, Egbert F. Smit, Joachim G.J.V. Aerts, Magdolen Youssef
Publikováno v:
Lung Cancer, 160, 44-49. Elsevier Ireland Ltd
Lung Cancer, 160, 44-49. ELSEVIER IRELAND LTD
Lung Cancer, 160, 44-49. ELSEVIER IRELAND LTD
Background: Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib in relapsed metastasized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f1412cde3a5dc0bde1bb210d253e089
https://doi.org/10.1016/j.lungcan.2021.08.002
https://doi.org/10.1016/j.lungcan.2021.08.002
Autor:
T. Jeroen N. Hiltermann, Jiacong Wei, Arja ter Elst, Pei Meng, Anthonie J. van der Wekken, Lennart Johansson, Mohamed Z. Alimohamed, Harry J.M. Groen, M. M. Terpstra, Anke van Rijk, Menno Tamminga, Klaas Kok, Rolof P G Gijtenbeek, Anke van den Berg, John W. G. van Putten, Jos A. Stigt, Frank J. G. Scherpen
Publikováno v:
Targeted Oncology
Targeted oncology. SPRINGER
Targeted oncology. SPRINGER
Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lung cancer on first-line tyrosine kinase inhibitor treatment has not been fully elucidated. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a98b3947a97ba38b576f5e80101316
https://research.rug.nl/en/publications/24efead6-38af-4452-aade-00211fe58ef2
https://research.rug.nl/en/publications/24efead6-38af-4452-aade-00211fe58ef2
Autor:
Gerald S M A Kerner, Ed Schuuring, Johanna Sietsma, Thijo J N Hiltermann, Remge M Pieterman, Gerard P J de Leede, John W G van Putten, Jeroen Liesker, Tineke E J Renkema, Peter van Hengel, Inge Platteel, Wim Timens, Harry J M Groen, CTMM Air Force Consortium
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e70346 (2013)
INTRODUCTION: In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We explored tumo
Externí odkaz:
https://doaj.org/article/a5ac43397f8b4543a3a97a47ad9f60cc
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 122
Objectives The tyrosine kinase inhibitor crizotinib may affect renal function. The mechanism of this effect is not understood. We aimed to get more insight by measuring renal hemodynamics in patients treated with crizotinib. Materials and methods Ren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b6b6c6e42870e36db760fc5a30f957e
https://pubmed.ncbi.nlm.nih.gov/30032830
https://pubmed.ncbi.nlm.nih.gov/30032830
Autor:
Henk Kramer, W. Rob Douma, Alie A. Smidt, Hendrik M. van Dullemen, John W. G. van Putten, Harry J.M. Groen
Publikováno v:
Respiratory Medicine, 99(2), 179-185. W B SAUNDERS CO LTD
Background: Encloscopic ultrasonography (EUS) is a novel method for staging of the mediastinum in lung cancer patients. The recent development of linear scanners enables safe and accurate fine-needle aspiration (FNA) of mediastinal and upper abdomina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3053bea0eee4135a2ecc35843e6636
https://doi.org/10.1016/j.rmed.2004.06.011
https://doi.org/10.1016/j.rmed.2004.06.011
Publikováno v:
Lung Cancer, 45(2), 255-262. ELSEVIER IRELAND LTD
Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-tine treatment in advanced non-small-cell lung cancer (NSCLC) patients who failed or relapsed after previous chemotherapy. Patients had to have unresectabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe303ba943add29068264eb0041fddd
https://doi.org/10.1016/j.lungcan.2004.02.006
https://doi.org/10.1016/j.lungcan.2004.02.006
Autor:
Harm H. Kampinga, J. G. Maring, John W. G. van Putten, Harry J.M. Groen, Floris M Wachters, Małgorzata Z. Zdzienicka
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 57(2), 553-562. ELSEVIER SCIENCE INC
Purpose: Gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is a potent radiosensitizer. The mechanism of dFdC-mediated radiosensitization is yet poorly understood. We recently excluded inhibition of DNA double-strand break (DSB) repair by nonhomolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f103f24759094525b8f64ec8aa82573
https://hdl.handle.net/11370/21b84fe5-8644-44e4-94c1-44109b6de774
https://hdl.handle.net/11370/21b84fe5-8644-44e4-94c1-44109b6de774
Autor:
Sander M. de Hosson, Marleen Woltman van Iersel, Johannes A. Langendijk, Joachim Widder, Steven R. Rutgers, A. Niezink, Eduard J. H. Boer, RM Pieterman, Anke W. J. Roenhorst, Nienke J. Dollekamp, Thijo J N Hiltermann, Harry J.M. Groen, Jan F. Ubbels, John W. G. van Putten, Harriet J. Elzinga, Anthonie J. van der Wekken, Denise Borger, Jan Kraan, Max Beijert, Annija H. D. van der Leest
Publikováno v:
Radiotherapy and Oncology, 115(1), 3-8. ELSEVIER IRELAND LTD
Background and purpose: Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5be4c8ce02f55667ddd815a0ae7600c
https://pubmed.ncbi.nlm.nih.gov/25866028
https://pubmed.ncbi.nlm.nih.gov/25866028
Autor:
RM Pieterman, Gerald S. M. A. Kerner, Ellen M Driever, Thijo J N Hiltermann, Edwin Blokzijl, Marc J F Mertens, Harry J.M. Groen, John W. G. van Putten, Erwin M. Wiegman, Jeroen J W Liesker, Leon F. A. van Dullemen, Tineke E. J. Renkema, Joachim Widder
Publikováno v:
Radiation oncology, 9:190. BMC
Radiation Oncology (London, England)
Radiation Oncology (London, England)
Background: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4b16e01c00b0cbaaa7457456cc3eaf9
https://research.rug.nl/en/publications/04de7199-f1c4-481f-8439-195dcd9f1a29
https://research.rug.nl/en/publications/04de7199-f1c4-481f-8439-195dcd9f1a29
